Leukemia News

In this edition, elevated cardiotoxicity risk for Black patients after chemotherapy; CV risk factor disparities in childhood cancer survivors; neural network helps identify potential targets for cancer drugs and more.

Children with acute lymphoblastic leukemia receiving maintenance therapy who lived in extreme poverty had nearly double the risk for relapse compared with children who did not live in extreme poverty, according to data published in Blood.

The FDA approved omidubicel-onlv, a donor cord blood-based cell therapy, to accelerate neutrophil recovery and reduce the risk for infection among patients with hematologic malignancies undergoing stem cell transplantation.

Cardiovascular disease, especially atherosclerotic CVD, was associated with increased risk for cancer diagnosis, according to a study published in JACC: CardioOncology.

Results of a large meta-analysis indicated that Black race was associated with greater odds of cardiotoxicity and HF diagnosis after chemotherapy compared with white and non-Black race, a speaker reported.

The disparate prevalence of cardiovascular risk factors among adult Black and Hispanic survivors of childhood cancer was comparable to the disparities in the American general population, researchers reported.

In this edition, DNA sequencing could identify patients with high-risk AML; review of major advances and challenges in chronic lymphocytic leukemia; FDA advisory panel backs polatuzumab vedotin and more.

Delirium appeared associated with higher ICU and hospital mortality, as well as increased length of stay, among critically ill patients with cancer, according to data published in JCO Oncology Practice.

The availability of highly effective targeted agents has changed the treatment landscape for chronic lymphocytic leukemia, but key questions about optimal strategies remain, according to a review published in JAMA.

Patients with hematologic malignancies reported significant improvement in quality of life after receiving chimeric antigen receptor T cells, results from a longitudinal study in Blood Advances showed.